<i>Rroid2</i> regulates effector-to-memory CD8 <sup>+</sup> T cell differentiation during infection in vivo
Abstract
CD8 + T cell differentiation has been associated with changes in the expression of long noncoding RNAs (lncRNAs). Yet, which and how lncRNAs regulate CD8 + T cell responses following infection in vivo remains incompletely understood. We performed deep RNA-seq to map the lncRNA expression landscape of CD8 + T cell subsets during infection and generated lncRNA knockout mouse models to evaluate the in vivo relevance of six lncRNAs. We identified Rroid2 to regulate effector CD8 + T cell function and effector-to-memory differentiation. Rroid2 -deficient mice displayed increased CD44 dim Foxp3 + regulatory T cells while the development of other immune cells, such as natural killer cells, was not affected. In CD8 + T cells, Rroid2 deficiency resulted in a fine-tuned downregulation of transcription factors Id2 and T-bet and impaired KLRG1 + and KLRG1 − effector CD8 + T cell proliferation and cytotoxicity as well as effector-to-memory CD8 + T cell differentiation. The human orthologue of Rroid2 , LINC01814 , is also upstream of the transcriptional regulator ID2 and is highly expressed in human memory CD8 + T cells. Taken together, Rroid2 represents a key regulatory layer that controls CD8 + T cell differentiation.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (11)
Julia Erber
Center for Cancer Research, Medical University of Vienna and Comprehensive Cancer Center
Carmen Stecher
Center for Cancer Research, Medical University of Vienna and Comprehensive Cancer Center
Valerie Plajer
Department of Immunobiology, Yale School of Medicine
Nina Braun
Center for Cancer Research, Medical University of Vienna and Comprehensive Cancer Center
William Mallard
Department of Stem Cell and Regenerative Biology, Harvard University
Loyal A. Goff
Department of Neuroscience, Johns Hopkins University
Iros Barozzi
Center for Cancer Research, Medical University of Vienna and Comprehensive Cancer Center
Thomas Mohr
Center for Cancer Research, Medical University of Vienna and Comprehensive Cancer Center
John L. Rinn
BioFrontiers Institute, University of Colorado Boulder
Richard A. Flavell
Department of Immunobiology, Yale School of Medicine
Dietmar Herndler-Brandstetter
Center for Cancer Research, Medical University of Vienna and Comprehensive Cancer Center